|
|
|
|
FDG-PET May Influence Management of Vulvar Carcinoma: Presented at SGO
-- Recent data suggest that positron emission tomography (PET) can play a useful diagnostic role for patients with vulvar carcinoma, researchers said here on March 15 at the Society of Gynecologic Oncologists (SGO) 41st Annual Meeting on Women's Cancer.
|
|
|
FDG-PET for Vulvar Carcinoma Diagnosis
PET can play a useful diagnostic role for patients with vulvar carcinoma, researchers said at the Society of Gynecologic Oncologists (SGO) 41st Annual Meeting on Women's Cancer.PET using fluorodeoxyglucose (FDG) as a tracer (FDG-PET) is widely used in...
|
|
|
Study: FDG PET helps improve management of vulvar cancer patients
Results of FDG PET scans changed the management in 18 of 19 vulvar cancer patien Study: FDG PET helps improve management of vulvar cancer patients.
|
|
|
US: Poorer girls not getting HPV vaccine for cervical cancer
One dose of the HPV vaccine Gardasil developed by Merck.HUMAN PAPILLOMAVIRUS, OR HPV, CAUSES ... 100% of cervical cancers 90% of anal cancers 40% of vulvar and vaginal cancers 12% of throat cancers 3% of oral cancers. Source: The New England...
|
|
|
HPV vaccine reduced further disease in women treated for cancer precursors
The Society for Gynecologic Oncologists 2010 Annual Meeting SAN FRANCISCO HPV vaccine quadrivalent (types 6, 11, 16 and 18) decreased HPV-related disease in women previously treated for cancer precursors, according to the post-hoc analysis of findings from two...
|
|
|
HPV vaccine reduced further disease in women treated for cancer precursors
The Society for Gynecologic Oncologists 2010 Annual Meeting SAN FRANCISCO HPV vaccine quadrivalent (types 6, 11, 16 and 18) decreased HPV-related disease in women previously treated for cancer precursors, according to the post-hoc analysis of findings from two...
|
|
|
Journal of the National Cancer Institute: News brief: HPV vaccines may reduce a wide range of genital diseases
Today's Medical & Research News News brief: HPV vaccines may reduce a wide range of genital diseases March 4th, 2010 Printer-Friendly Version Adolescent Medicine Biotechnology Cancer Vaccines Cervical Cancer Cervical Carcinoma Dermatology Diagnostics...
|
|
|
Aurora Health Care establishes new clinic for treating chronic vulvar pain
It is a sensitive subject for many women.The issue is chronic vulvar pain, and it impacts one out of six women at some point in their lives. However, most women are unaware of their treatment options. To fill this need, the Optimal Health and...
|
|
|
Aurora Women's Pavilion Center for Sexual Health & Wellness Receives Grant to Treat Vulvar Pain
Companies mentioned in this article: Aurora Health Care MILWAUKEE, March 2 /PRNewswire/ -- It is a sensitive subject for many women.The issue is chronic vulvar pain, and it impacts one out of six women at some point in their lives. However, most...
|
|
|
In Phase III Data Mercks GARDASIL Was Efficacious Against Anal Disease Caused by HPV-6,11,16 and 18
Merck & Co., Inc.announced today that in new Phase III data, GARDASIL [Human Papillomavirus Quadrivalent (Types 6, 11, 16 and 18) Vaccine, Recombinant] was 77.5 percent (95 percent CI: 39.6, 93.3) efficacious against anal intraepithelial neoplasia ...
|
|
|
In Phase III Data Merck's GARDASIL(R) Was Efficacious Against Anal Disease Caused by HPV-6,11,16 and 18
Investigational Data Also Presented on Efficacy Against HPV 6,11,16 and 18 - Related Persistent Infection, CIN and EGL in Women Aged 24 Through 45 Nave to the Relevant HPV Type WHITEHOUSE STATION, N.J.--(HSMN NewsFeed)--Merck & Co., Inc.announced today...
|
|
|
In Phase III Data Merck's Gardasil Was Efficacious Against Anal Disease Caused by HPV-6,11,16 and 18
Investigational Data Also Presented on Efficacy Against HPV 6,11,16 and 18 -Related Persistent Infection, CIN and EGL in Women Aged 24 Through 45 Nave to the Relevant HPV Type WHITEHOUSE STATION, N.J.--(BUSINESS WIRE)--Feb 17, 2010 - Merck & Co., Inc.
|
|
|
Gardasil Helps Prevent Anal Cancer In Men, Showed New Study
KIRKLAND, QC, Feb.17 /CNW Telbec/ - In a new phase III study, GARDASIL(R) (Quadrivalent Human Papillomavirus (Types 6, 11, 16 and 18) Recombinant Vaccine) prevented 77.5 per cent of anal intraepithelial neoplasia (AIN) associated with human papillomavirus ...
|
|
|
Merck's Study Show Gardasil Effective In Anal Diseases In Gays - Update
2/17/2010 3:22 PM ET RELATED NEWS Trade MRK now with TOP MARKET NEWS (RTTNews) - Wednesday, Merck & Co., Inc.(MRK: News ) said its phase 3 trial of Gardasil was efficacious in preventing anal diseases and anal cancer in gay men. The drug was found to...
|
|
|
In Phase III Data Merck's GARDASIL Was Efficacious Against Anal Disease Caused by HPV-6,11,16 and 18
Investigational Data Also Presented on Efficacy Against HPV 6,11,16 and 18 -Related Persistent Infection, CIN and EGL in Women Aged 24 Through 45 Nave to the Relevant HPV Type WHITEHOUSE STATION, N.J.(BUSINESS WIRE) Merck & Co., Inc.announced today...
|
|
|
In Phase III Data Merck's Gardasil Was Efficacious Against Anal Disease Caused by HPV-6,11,16 and 18
Investigational Data Also Presented on Efficacy Against HPV 6,11,16 and 18 -Related Persistent Infection, CIN and EGL in Women Aged 24 Through 45 Nave to the Relevant HPV Type WHITEHOUSE STATION, N.J.--(BUSINESS WIRE)--Feb 17, 2010 - Merck & Co., Inc.
|
|
|
Vaccination against HPV-16 for Vulvar Intraepithelial Neoplasia
_ Vaccination against HPV-16 for Vulvar Intraepithelial Neoplasia.
|
|
|
GARDASIL(R) helps prevent anal cancer in men, showed new study
KIRKLAND, QC, Feb.17 /CNW Telbec/ - In a new phase III study, GARDASIL(R) (Quadrivalent Human Papillomavirus (Types 6, 11, 16 and 18) Recombinant Vaccine) prevented 77.5 per cent of anal intraepithelial neoplasia (AIN) associated with human papillomavirus ...
|
|
|
GARDASIL(R) helps prevent anal cancer in men, showed new study
KIRKLAND, QC, Feb.17 /CNW Telbec/ - In a new phase III study, GARDASIL(R) (Quadrivalent Human Papillomavirus (Types 6, 11, 16 and 18) Recombinant Vaccine) prevented 77.5 per cent of anal intraepithelial neoplasia (AIN) associated with human papillomavirus ...
|
|
|
Phase III study: GARDASIL prevents 77.5% of pre-cursor lesions to anal cancer
In a new phase III study, GARDASIL(R) (Quadrivalent Human Papillomavirus (Types 6, 11, 16 and 18) Recombinant Vaccine) prevented 77.5 per cent of anal intraepithelial neoplasia (AIN) associated with human papillomavirus (HPV) types 6, 11, 16 and 18 in 16-to-26...
|
|
|
GARDASIL(R) helps prevent anal cancer in men, showed new study
KIRKLAND, QC, Feb.17 /CNW Telbec/ - In a new phase III study, GARDASIL(R) (Quadrivalent Human Papillomavirus (Types 6, 11, 16 and 18) Recombinant Vaccine) prevented 77.5 per cent of anal intraepithelial neoplasia (AIN) associated with human papillomavirus ...
|
|
|
Second vaccine against HPV approved
TORONTO Canadian women who want to be immunized against HPV, a family of viruses that causes cervical cancer, now have a choice of two competing vaccines.Health Canada has approved Cervarix, a product of GlaxoSmithKline Inc., which is expected to be...
|
|
|
Society of Gynecologic Oncologists to Host 41st Annual Meeting on Women's Cancer
The Society of Gynecologic Oncologists (SGO) will host its 41st Annual Meeting on Women's Cancer March 14-17, 2010 at the Moscone West Convention Center in San Francisco, California.This year's meeting will feature more than 434 scientific presentations in...
|
|
|
Health Canada approves second vaccine against HPV, a product of GlaxoSmithKline
TORONTO _ Canadian women who want to be immunized against HPV, a family of viruses that causes cervical cancer, now have a choice of two competing vaccines.Health Canada has approved Cervarix, a product of GlaxoSmithKline Inc., which is expected to be...
|
|
|
Society Of Gynecologic Oncologists To Host 41st Annual Meeting On Women's Cancer
The Society of Gynecologic Oncologists (SGO) will host its 41st Annual Meeting on Women's Cancer March 14-17, 2010 at the Moscone West Convention Center in San Francisco, California.This year's meeting will feature more than 434 scientific presentations in...
|
